0.1003
price up icon0.10%   0.0001
after-market 시간 외 거래: .10 -0.0003 -0.30%
loading

Geovax Labs Inc 주식(GOVXW)의 최신 뉴스

pulisher
Feb 04, 2025

Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Analysts review Geovax Labs Inc’s rating - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - Citybuzz

Feb 04, 2025
pulisher
Feb 04, 2025

GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance

Feb 04, 2025
pulisher
Feb 03, 2025

Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı

Feb 03, 2025
pulisher
Feb 03, 2025

GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance

Feb 03, 2025
pulisher
Feb 03, 2025

GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

GeoVax shareholders approve warrant exercises - MSN

Jan 31, 2025
pulisher
Jan 29, 2025

Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance

Jan 29, 2025
pulisher
Jan 27, 2025

GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance

Jan 27, 2025
pulisher
Jan 25, 2025

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

GeoVax Labs Stockholders Approve Warrant Exercise Proposals - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

GeoVax shareholders approve warrant exercises By Investing.com - Investing.com Australia

Jan 23, 2025
pulisher
Jan 18, 2025

D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial - Yahoo Finance

Jan 15, 2025
pulisher
Jan 15, 2025

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now - GlobeNewswire Inc.

Jan 15, 2025
pulisher
Jan 13, 2025

GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 - Yahoo Finance

Jan 13, 2025
pulisher
Jan 08, 2025

GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 - Yahoo Finance

Jan 08, 2025
pulisher
Jan 02, 2025

Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World

Jan 02, 2025
pulisher
Dec 31, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Dec 31, 2024
pulisher
Dec 18, 2024

GeoVax adjourns Special Meeting due to low quorum - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia

Dec 18, 2024
pulisher
Dec 09, 2024

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times

Dec 09, 2024
pulisher
Dec 09, 2024

GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan

Dec 09, 2024
pulisher
Dec 08, 2024

GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN

Dec 08, 2024
pulisher
Dec 06, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Dec 06, 2024
pulisher
Dec 02, 2024

Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Dec 02, 2024
pulisher
Nov 30, 2024

Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com

Nov 30, 2024
pulisher
Nov 30, 2024

Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN

Nov 30, 2024
pulisher
Nov 29, 2024

3 Penny Stocks Ready to Break Out in 2025 - sharewise

Nov 29, 2024
pulisher
Nov 27, 2024

Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com

Nov 27, 2024
pulisher
Nov 26, 2024

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire

Nov 26, 2024
pulisher
Nov 26, 2024

GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 23, 2024

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN

Nov 23, 2024
pulisher
Nov 23, 2024

Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World

Nov 23, 2024
pulisher
Nov 20, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire

Nov 20, 2024
pulisher
Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards - Investing.com India

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial - Investing.com India

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - The Manila Times

Nov 19, 2024
pulisher
Nov 16, 2024

Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia

Nov 15, 2024
$81.01
price up icon 4.02%
$20.62
price up icon 3.20%
$353.43
price down icon 0.32%
$5.09
price down icon 0.20%
biotechnology ONC
$222.91
price down icon 0.21%
$117.14
price down icon 2.24%
자본화:     |  볼륨(24시간):